BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20145268)

  • 21. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.
    Pende D; Marcenaro S; Falco M; Martini S; Bernardo ME; Montagna D; Romeo E; Cognet C; Martinetti M; Maccario R; Mingari MC; Vivier E; Moretta L; Locatelli F; Moretta A
    Blood; 2009 Mar; 113(13):3119-29. PubMed ID: 18945967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human NK cells: From surface receptors to clinical applications.
    Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
    Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.
    Jaiswal SR; Zaman S; Nedunchezhian M; Chakrabarti A; Bhakuni P; Ahmed M; Sharma K; Rawat S; O'donnell P; Chakrabarti S
    Cytotherapy; 2017 Apr; 19(4):531-542. PubMed ID: 28131632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
    Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The early expansion of anergic NKG2A
    Roberto A; Di Vito C; Zaghi E; Mazza EMC; Capucetti A; Calvi M; Tentorio P; Zanon V; Sarina B; Mariotti J; Bramanti S; Tenedini E; Tagliafico E; Bicciato S; Santoro A; Roederer M; Marcenaro E; Castagna L; Lugli E; Mavilio D
    Haematologica; 2018 Aug; 103(8):1390-1402. PubMed ID: 29700172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide.
    Willem C; Makanga DR; Guillaume T; Maniangou B; Legrand N; Gagne K; Peterlin P; Garnier A; Béné MC; Cesbron A; Le Bourgeois A; Chevallier P; Retière C
    J Immunol; 2019 Apr; 202(7):2141-2152. PubMed ID: 30787107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.
    Zhao XY; Yu XX; Xu ZL; Cao XH; Huo MR; Zhao XS; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    Blood Adv; 2019 Dec; 3(24):4312-4325. PubMed ID: 31869417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells.
    Falk CS; Steinle A; Schendel DJ
    J Exp Med; 1995 Oct; 182(4):1005-18. PubMed ID: 7561674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation.
    Moretta L; Locatelli F; Pende D; Marcenaro E; Mingari MC; Moretta A
    Blood; 2011 Jan; 117(3):764-71. PubMed ID: 20889923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural killer-cell KIR repertoire reconstitution after haploidentical SCT.
    Stern M; de Angelis C; Urbani E; Mancusi A; Aversa F; Velardi A; Ruggeri L
    Bone Marrow Transplant; 2010 Nov; 45(11):1607-10. PubMed ID: 20173785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypic and functional analysis of the HLA-class I-specific inhibitory receptors of natural killer cells isolated from peripheral blood of patients undergoing bone marrow transplantation from matched unrelated donors.
    Vitale C; Pitto A; Benvenuto F; Ponte M; Bellomo R; Frassoni F; Mingari MC; Bacigalupo A; Moretta L
    Hematol J; 2000; 1(2):136-44. PubMed ID: 11920181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation.
    Locatelli F; Bauquet A; Palumbo G; Moretta F; Bertaina A
    Immunol Lett; 2013; 155(1-2):21-3. PubMed ID: 24091162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human NK receptors: from the molecules to the therapy of high risk leukemias.
    Moretta L; Locatelli F; Pende D; Sivori S; Falco M; Bottino C; Mingari MC; Moretta A
    FEBS Lett; 2011 Jun; 585(11):1563-7. PubMed ID: 21554879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
    Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
    Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deciphering the biology of KIR2DL3
    David G; Willem C; Legrand N; Djaoud Z; Mérieau P; Walencik A; Guillaume T; Gagne K; Chevallier P; Retière C
    Sci Rep; 2021 Aug; 11(1):15782. PubMed ID: 34349169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor.
    Davies SM; Ruggieri L; DeFor T; Wagner JE; Weisdorf DJ; Miller JS; Velardi A; Blazar BR
    Blood; 2002 Nov; 100(10):3825-7. PubMed ID: 12393440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.
    Huenecke S; Zimmermann SY; Kloess S; Esser R; Brinkmann A; Tramsen L; Koenig M; Erben S; Seidl C; Tonn T; Eggert A; Schramm A; Bader P; Klingebiel T; Lehrnbecher T; Passweg JR; Soerensen J; Schwabe D; Koehl U
    J Immunother; 2010; 33(2):200-10. PubMed ID: 20145545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Modulation Properties of Zoledronic Acid on TcRγδ T-Lymphocytes After TcRαβ/CD19-Depleted Haploidentical Stem Cell Transplantation: An analysis on 46 Pediatric Patients Affected by Acute Leukemia.
    Merli P; Algeri M; Galaverna F; Milano GM; Bertaina V; Biagini S; Girolami E; Palumbo G; Sinibaldi M; Becilli M; Leone G; Boccieri E; Grapulin L; Gaspari S; Airoldi I; Strocchio L; Pagliara D; Locatelli F
    Front Immunol; 2020; 11():699. PubMed ID: 32477328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
    Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E;
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
    Boudreau JE; Giglio F; Gooley TA; Stevenson PA; Le Luduec JB; Shaffer BC; Rajalingam R; Hou L; Hurley CK; Noreen H; Reed EF; Yu N; Vierra-Green C; Haagenson M; Malkki M; Petersdorf EW; Spellman S; Hsu KC
    J Clin Oncol; 2017 Jul; 35(20):2268-2278. PubMed ID: 28520526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.